Vagenakis A G, Braverman L E
Med Clin North Am. 1975 Sep;59(5):1075-88. doi: 10.1016/s0025-7125(16)31958-7.
The administration of pharmacologic quantities of iodine such as iodides for the treatment of pulmonary disease, organic iodine present in medications and x-ray contrast dyes, and the ingestion of iodine-rich natural foods, may result in goiter, hypothyroidism, or hyperthyroidism, especially in patients with underlying thyroid disease. Medications containing iodide may induce hypothroidism in euthyroid patients with Hashimoto's thyroiditis, 131I or surgically treated Graves' disease, or following hemithyroidectomy for nodules; and they may induce hyperthyroidism in patients with endemic iodine-deficient goiter, autonomous nodules or nontoxic nodular goiter, or in patients recently treated with antithyroid drugs for Graves' disease. Rarely, hypothyroidism or hyperthyroidism may develop in patients with completely normal thyroid function during administration of iodide. The etiology of iodide-induced goiter and hypothyroidism in patients with cystic fibrosis remains obscure. Iodide-induced myxedema may also occur in patients receiving drugs which alter thyroid function, such as lithium, phenazone, and sulfisoxazole. Finally, iodides do have a role in the treatment of hyperthyroidism but their use should probably be restricted to thyroid storm, preoperative preparation of the hyperthyroid patient, and following 131I treatment.
给予药理学剂量的碘,如用于治疗肺部疾病的碘化物、药物和X射线造影剂中存在的有机碘,以及摄入富含碘的天然食物,可能会导致甲状腺肿、甲状腺功能减退或甲状腺功能亢进,尤其是在患有潜在甲状腺疾病的患者中。含碘药物可能会在患有桥本甲状腺炎的甲状腺功能正常的患者、接受131I治疗或手术治疗的格雷夫斯病患者,或因结节进行半甲状腺切除术后诱发甲状腺功能减退;它们可能会在患有地方性碘缺乏性甲状腺肿、自主性结节或非毒性结节性甲状腺肿的患者中,或在最近因格雷夫斯病接受抗甲状腺药物治疗的患者中诱发甲状腺功能亢进。在服用碘化物期间,甲状腺功能完全正常的患者很少会出现甲状腺功能减退或亢进。囊性纤维化患者中碘化物诱发的甲状腺肿和甲状腺功能减退的病因仍不清楚。接受改变甲状腺功能的药物(如锂、非那宗和磺胺异恶唑)治疗的患者也可能发生碘化物诱发的黏液性水肿。最后,碘化物确实在甲状腺功能亢进的治疗中发挥作用,但它们的使用可能应仅限于甲状腺危象、甲状腺功能亢进患者的术前准备以及131I治疗后。